Lilly completes acquisition of SGX Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Lilly has completed the acquisition of SGX Pharmaceuticals, the San-Diego based biotechnology company focused on oncology. A majority of SGX shareholders voted in favour of the merger agreement with Lilly. Under the agreement, Lilly acquires all outstanding shares of SGX common stock at $3.00 per share. All other closing conditions have been met. Lilly and SGX have been in partnership since 2003 to explore three-dimensional structures of Lilly's drug targets using SGX's X-ray crystallography technology (Scrip Online, July 9th, 2008).
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.